KOVE Medical raises €1.7 million to improve safety of foetal surgery

KOVE Medical has raised €1.7 million to support first-in-human studies of an implantable device designed to reduce preterm birth risk after foetal surgery.

The University of Zurich spin-off is developing a device designed to close defects left by surgical instruments following fetoscopy, a minimally invasive procedure performed inside the womb.

Fetoscopies can treat life-threatening conditions before birth but require surgical instruments to pass through the uterine wall and amniotic sac.

This can weaken the protective membrane, causing fluid leakage or rupture and often leading to preterm birth.

KOVE Medical said in a statement on LinkedIn: “This is a crucial step forward for our company, and we are incredibly grateful for the strong support and trust from our syndicate of visionary angel investors.”

KOVE Medical says its device closes the defect at the end of the procedure, stabilising the membrane and preventing complications. The aim is to make in-utero interventions safe enough to become a standard method of care.

The company plans to use the seed funding to reach first-in-human studies, a key milestone for a medical device seeking regulatory approval.

The CHF1.6m round was backed by a syndicate of angel investors.